ライフサイエンスコーパス: first-line treatment

1 significant treatment-related toxicities of first-line treatment.

2 rease) as oral targeted therapies become the first-line treatment.

3 d time to disease progression after starting first-line treatment.

4 nd the responsiveness of MDR tuberculosis to first-line treatment.

5 with high-potency topical corticosteroids as first-line treatment.

6 over 4 days with mesna and pegfilgrastim) as first-line treatment.

7 een revised to include behavioral therapy as first-line treatment.

8 evelop recurrent or refractory disease after first-line treatment.

9 g gemcitabine, a nucleoside analog used as a first-line treatment.

10 re more prevalent in the rotating arm during first-line treatment.

11 -compulsive disorder (OCD) are refractory to first-line treatment.

12 etastatic NETs and disease progression after first-line treatment.

13 , suggesting an alternative approach to this first-line treatment.

14 ne would be more effectively positioned as a first-line treatment.

15 re EGFR-blocking antibodies are approved for first-line treatment.

16 ally requires high-dose systemic steroids as first-line treatment.

17 re relapses and may require reinforcement of first-line treatment.

18 eta 1a in patients who have relapsed despite first-line treatment.

19 hout disease progression after completion of first-line treatment.

20 14% of patients received pulmonary RT during first-line treatment.

21 study sites in 12 countries after failure of first-line treatment.

22 ing ART, in line with nationally recommended first-line treatment.

23 eak and PLPS and, thus, should be considered first-line treatment.

24 best tolerated of the three and the standard first-line treatment.

25 erapies leaves uncertainty regarding optimal first-line treatment.

26 symptomatic relapses after the completion of first-line treatment.

27 urvival in patients with SCLC who respond to first-line treatment.

28 y, and should be considered as an option for first-line treatment.

29 vere traumatic brain injury is refractory to first-line treatments.

30 Of 221 patients who did not improve with first-line treatment, 125 (57%) received second-line imm

31 ation therapies (ACTs) are used worldwide as first-line treatment against confirmed or suspected Plas

32 d isolates had antimicrobial resistance to a first-line treatment agent.

33 Resistance to first-line treatment agents in patients with Salmonella

34 ot feasible, misoprostol might be a suitable first-line treatment alternative for post-partum haemorr

35 rinotecan, leucovorin, and fluorouracil as a first-line treatment among pcCRC (HR for OS = 0.62, P =

36 esponse rates of more than 90% when given as first-line treatment and a significant improvement in su

37 All patients were refractory to first-line treatment and harbored a BRAF(V600E) mutation

38 increasingly MUD HSCT is being considered as first-line treatment and is also being considered more f

39 aliplatin with or without bevacizumab in the first-line treatment and subsequent fluorouracil, leucov

40 Trastuzumab, pertuzumab, and taxane for first-line treatment and T-DM1 for second-line treatment

41 past 15 years because of improved access to first-line treatment and vector control.

42 c reviews and/or meta-analyses, 30 trials on first-line treatment, and 29 trials on second-line and s

43 or docetaxel, trastuzumab, and pertuzumab in first-line treatment, and the EMILIA trial found surviva

44 who have progressive disease before starting first-line treatment, and those with mutations should be

45 ests, features of the lung-cancer cases, and first-line treatments, and we estimated the performance

46 problem, and antidepressants are the current first-line treatment approach.

47 Behavior therapy remains the recommended first-line treatment approach; pharmacotherapy is someti

48 istant strains of Mycobacterium tuberculosis First-line treatments are anchored by two antibiotics, r

49 omy should be offered endovascular repair as first-line treatment at experienced vascular centers.

50 alth system to deliver interventions such as first-line treatment at optimal coverage and quality.

51 t of appendiceal abscess is recommended as a first line treatment, but some controversy exists.

52 n-containing regimens could be an option for first-line treatment, but its efficacy should be evaluat

53 The mainstay of first-line treatment by professionals included corticoid

54 ponse reported for other agents when used as first-line treatment, certainly call into question the l

55 he purpose of this article was to inform the first-line treatment choice between cognitive-behavioral

56 e, and prednisone (CHOP) remain the standard first-line treatment choice for systemic ALCL, but in ma

57 capacity than patients who have responded to first-line treatment (Cohen's d=0.9191 (whole striatum),

58 First-line treatment consisted of either an 8-week alter

59 First-line treatment consisted of steroids alone (27.6%)

60 haracterized by poor rates of remission with first-line treatments, contributing to the chronic illne

61 tered to 92% of patients, mostly as standard first-line treatment corresponding to stage; 8% of patie

62 Antimonial compounds are used as first-line treatment drugs, but their toxicity, which ca

63 e randomly assigned to receive either ECX as first-line treatment (ECX arm) or FOLFIRI (FOLFIRI arm).

64 ther investigation to establish ECT's use as first line treatment especially in basocellular carcinom

65 line immunotherapy is usually effective when first-line treatments fail.

66 The addition of bevacizumab to ET in first-line treatment failed to produce a statistically s

67 se-specific survival (DSS), and freedom from first-line treatment failure (FFTF) and an independent m

68 n is significantly predictive (P = .0009) of first-line treatment failure and symptomatic relapse and

69 dults and adolescents with HIV infection and first-line treatment failure to receive a ritonavir-boos

70 mmends simple wound care or local therapy as first-line treatment, followed or replaced by systemic t

71 Although adrenaline is recommended as first line treatment for anaphylaxis, it is often not ut

72 otherapeutic agents including gemcitabine, a first line treatment for pancreatic cancer.

73 ese risks, women do not consistently receive first line treatment for the early stages of hypertensio

74 Conservative management is the first line treatment for TON.

75 to an unselected HER2/neu-negative cohort as first-line treatment for ABC.

76 en in the author's opinion it may become the first-line treatment for acute respiratory failure.

77 re that family interventions are the current first-line treatment for adolescent anorexia nervosa and

78 FOLFIRI as first-line treatment for advanced gastric and EGJ cancer

79 citabine and docetaxel versus doxorubicin as first-line treatment for advanced or metastatic soft-tis

80 Amikacin is a first-line treatment for Aeromonas infection due to high

81 First-line treatment for anaphylaxis is intramuscular ad

82 ry in experienced hands is safe and feasible first-line treatment for appendiceal abscess.

83 Although corticosteroid is the first-line treatment for asthma, a subset of patients is

84 ven as adjuvant for at least 12 months or as first-line treatment for at least 6 months).

85 orally administered methylphenidate (MPH), a first-line treatment for attention deficit hyperactivity

86 Although lithium preparations remain first-line treatment for bipolar disorder, risk for deve

87 Steroids are the appropriate first-line treatment for both.

88 ibitors that also inhibit SFKs could provide first-line treatment for BRAF and NRAS mutant melanomas

89 tely 50% of isolates, using fidaxomicin as a first-line treatment for CDI is not cost-effective.

90 d brief therapy and might be considered as a first-line treatment for children with anxiety problems.

91 omnia (CBT-i) is now commonly recommended as first-line treatment for chronic insomnia.

92 Fluoropyrimidines are the first-line treatment for colorectal cancer, but their ef

93 ents who experienced relapse after receiving first-line treatment for disseminated disease.

94 colchicine should be probably regarded as a first-line treatment for either acute or recurrent peric

95 ide (LEN) to rituximab-bendamustine (R-B) as first-line treatment for elderly patients with MCL.

96 Temozolomide (TMZ) is first-line treatment for gliomas and recurrent brain met

97 eleasing intrauterine system is considered a first-line treatment for heavy menstrual bleeding and sh

98 lus trastuzumab plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast

99 iptase inhibitors (NRTIs) are recommended as first-line treatment for HIV, and coformulated fixed-dos

100 First-line treatment for Hymenoptera sting anaphylaxis i

101 Corticosteroids are still the standard first-line treatment for immune thrombocytopenic purpura

102 Supervised exercise is recommended as a first-line treatment for intermittent claudication.

103 ab, a B cell-depleting agent, has become the first-line treatment for ITP; however, patients with ref

104 Eflornithine combined with nifurtimox is the first-line treatment for late-stage T b gambiense.

105 consider with their patients when selecting first-line treatment for locally advanced or metastatic

106 For many years, first-line treatment for locally advanced or metastatic

107 ecoming resistant to artemesinin, a standard first-line treatment for malaria.

108 is percutaneous minimally invasive therapy a first-line treatment for many patients at extreme risk f

109 ular endothelial growth factor), is standard first-line treatment for metastatic colorectal cancer.

110 Regorafenib has antitumour activity as first-line treatment for metastatic or unresectable rena

111 f multiple plastic stents in parallel is the first-line treatment for most benign biliary strictures;

112 Although fluid restriction remains the first-line treatment for most forms of chronic hyponatre

113 TION: Doxorubicin should remain the standard first-line treatment for most patients with advanced sof

114 ugar in the diet and 'lifestyle change' as a first-line treatment for NAFLD; however, the benefits fr

115 Platinum-based chemotherapy is the first-line treatment for non-small cell lung cancer, but

116 Platinum-based chemotherapy is the standard first-line treatment for patients with advanced non-smal

117 of local administration of corticosteroids, first-line treatment for patients with bronchial asthma,

118 ine therapy is preferable to chemotherapy as first-line treatment for patients with estrogen receptor

119 everolimus to trastuzumab and paclitaxel as first-line treatment for patients with HER2-positive adv

120 uzumab to docetaxel and trastuzumab (THP) as first-line treatment for patients with human epidermal g

121 Cetuximab Versus FOLFIRI Plus Bevacizumab as First-Line Treatment For Patients With Metastatic Colore

122 Cetuximab Versus FOLFIRI Plus Bevacizumab as First-Line Treatment For Patients With Metastatic Colore

123 tion with cisplatin and gemcitabine (CGB) as first-line treatment for patients with metastatic UC.

124 bination chemotherapy is considered standard first-line treatment for patients with metastatic urothe

125 Regarding first-line treatment for patients with non-squamous cell

126 nuous positive airway pressure (CPAP) is the first-line treatment for patients with symptomatic obstr

127 , chloroquine (CQ) without primaquine is the first-line treatment for Plasmodium vivax in malarious a

128 Chloroquine is the first-line treatment for Plasmodium vivax malaria in mos

129 ormulations of topical azole antifungals are first-line treatment for pregnant women, oral fluconazol

130 Ursodeoxycholic acid, the standard first-line treatment for primary biliary cholangitis, is

131 The first-line treatment for primary prophylaxis of esophage

132 serotonin reuptake inhibitors (SSRIs) are a first-line treatment for PTSD, but treatment mechanisms

133 inib is an antiangiogenic therapy given as a first-line treatment for renal cell carcinoma (RCC).

134 Oral glucocorticoids are the standard first-line treatment for sarcoidosis.

135 Cyclosporin A is recommended as first-line treatment for short-term use.

136 elieve nonoperative management should be the first-line treatment for stable OCD lesions in children.

137 pelvic-floor muscle training is advocated as first-line treatment for stress urinary incontinence; mi

138 First-line treatment for symptomatic OSA is continuous p

139 fludarabine plus rituximab as one acceptable first-line treatment for symptomatic patients with CLL.

140 le of diet and lifestyle modification as the first-line treatment for the reduction of raised serum l

141 rgical resection should be considered as the first-line treatment for these patients.

142 was more common among those who discontinued first-line treatment for this reason.

143 Gemcitabine-docetaxel remains a standard first-line treatment for uLMS.

144 Artemisinin-based combination therapy is the first-line treatment for uncomplicated falciparum malari

145 eatment guidelines that had endorsed ACTs as first-line treatment for uncomplicated malaria.

146 artemisinin-based combination therapy as the first-line treatment for uncomplicated Plasmodium falcip

147 ed corticosteroids (ICSs) are widely used as first-line treatment for various chronic respiratory ill

148 e exercise or psychological interventions as first-line treatments for CRF.

149 First-line treatments for idiopathic multicentric Castle

150 Antipsychotic medications, the first-line treatments for moderate to severe tics, are o

151 ccelerated fibrosarcoma (RAF) inhibitors are first-line treatments for patients harboring V600E/K mut

152 sone (CHOP), nowadays represent the standard first-line treatment; for patients who achieve a satisfa

153 del(17p) and relapsed CLL from 2014, and for first-line treatment from 2016 onward.

154 cs, upfront treatment, front-line treatment, first-line treatment, front-line treatments, first-line

155 first-line treatment, front-line treatments, first-line treatments, front-line therapy, front-line th

156 Currently, the first line treatment, gemcitabine, is only effective in

157 ltivariate analysis, ineffective response to first-line treatment (hazard ratio [HR]: 20.6; P = 0.01)

158 previous trastuzumab treatment (adjuvant vs first-line treatment), hormone receptor status (oestroge

159 Alemtuzumab given intravenously as first-line treatment in 32 patients resulted in an overa

160 bitor ribociclib combined with letrozole for first-line treatment in 668 postmenopausal women with HR

161 Cladribine was used as the first-line treatment in 9 patients and as later-line tre

162 first such study to address the question of first-line treatment in a randomized trial.

163 s and validates new criteria for response to first-line treatment in AL amyloidosis, based on their a

164 Lithium is a first-line treatment in bipolar disorder, but individual

165 LY2828360 may be useful as a first-line treatment in chemotherapy-induced neuropathic

166 rapy was not superior to IFN/bevacizumab for first-line treatment in clear-cell mRCC.

167 and early clinical efficacy of this drug as first-line treatment in combination with standard or mod

168 ghly effective antileishmanial agent used as first-line treatment in different formulations in viscer

169 Fluconazole is recommended as first-line treatment in invasive candidiasis in children

170 fficult decision given that these agents are first-line treatment in many guidelines.

171 to support conservative interventions as the first-line treatment in men with LUTS.

172 of adding IMA901 to sunitinib, the standard first-line treatment in metastatic renal cell carcinoma

173 trong recommendation for use and proposal as first-line treatment in neuropathic pain for tricyclic a

174 Maintenance erlotinib after first-line treatment in ovarian cancer did not improve p

175 tologous stem-cell transplantation (ASCT) as first-line treatment in patients with diffuse large B-ce

176 e of ATRA plus arsenic trioxide as preferred first-line treatment in patients with low- or intermedia

177 utcome in relation to prognostic factors and first-line treatment in patients with MCL in a populatio

178 overall survival when added to sunitinib as first-line treatment in patients with metastatic renal c

179 ablation with antiarrhythmic drug therapy as first-line treatment in patients with paroxysmal atrial

180 ablation with antiarrhythmic drug therapy as first-line treatment in patients with paroxysmal atrial

181 First-line treatment in patients with significant altera

182 a; therefore, R-CHOP-21 remains the standard first-line treatment in patients with this haematologica

183 h to the management of VT with ablation as a first-line treatment in postinfarct patients presenting

184 , further supporting the roll-out of NECT as first-line treatment in second-stage Trypanosoma brucei

185 These findings support the use of PMC as first-line treatment in selected patients with calcific

186 ho progressed within 9 months after start of first-line treatment in the docetaxel plus nintedanib gr

187 t GalT-KO skin grafts could provide an early first-line treatment in the management of severe burns t

188 to assess the effectiveness of FOLFIRINOX as first-line treatment in this patient population.

189 R) for hepatocellular carcinoma (HCC) as the first-line treatment in transplantable patients followed

190 ctures; bisphosphonates are commonly used as first-line treatment in women who do not have contraindi

191 First line treatment is radiotherapy, which many patient

192 than in early-stage disease, and the optimum first-line treatment is unclear.

193 liver transplantation cannot be considered a first-line treatment, it is a valid therapeutic option i

194 o be susceptible when this drug is used as a first-line treatment modality.

195 ts for whom carbamazepine was considered the first-line treatment, most of whom were newly diagnosed

196 Reduction in immunosuppression is the first line treatment of HHV-8 infection.

197 -directed small molecule therapy to standard first-line treatment of acute myeloid leukemia (AML) has

198 uximab was added to standard chemotherapy in first-line treatment of advanced colorectal cancer with

199 ectedin plus doxorubicin with doxorubicin as first-line treatment of advanced STS patients.

200 t show superiority over doxorubicin alone as first-line treatment of advanced STS.

201 drenaline is life-saving and constitutes the first-line treatment of anaphylaxis.

202 Erythropoiesis stimulating agents remain the first-line treatment of anemia in most lower-risk MDS wi

203 chemotherapy regimen widely used in Asia-for first-line treatment of Asian patients with EGFR mutatio

204 of antifungal agents is considered to be the first-line treatment of bloodstream infections (BSI) due

205 nd CsA appeared to be safe and effective for first-line treatment of cGVHD.

206 y with methylphenidate (MPH) seems to be the first-line treatment of choice in adults with attention-

207 cribed cholesterol-lowering drugs that are a first-line treatment of coronary artery disease and athe

208 these antidepressants, with usual care, for first-line treatment of depression in Alzheimer's diseas

209 bizumab, aflibercept, laser, and sham in the first-line treatment of diabetic macular edema (DME) to

210 evacizumab to cisplatin and etoposide in the first-line treatment of ED-SCLC had an acceptable toxici

211 kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation-positive non-small

212 pport combined chemotherapy and erlotinib in first-line treatment of EGFR-selected advanced NSCLC, an

213 long-term efficacy and should be considered first-line treatment of esophageal achalasia.

214 Aromatase inhibitors are the major first-line treatment of estrogen receptor-positive breas

215 erlotinib compared with chemotherapy for the first-line treatment of European patients with advanced

216 s are being developed, and their role in the first-line treatment of frail patients or those who rela

217 lus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric c

218 trospective, SBRT appears to be a reasonable first-line treatment of inoperable, larger HCC.

219 tients of any age who received FOLFIRINOX as first-line treatment of locally advanced pancreatic canc

220 (CDDP) versus concomitant cetuximab (CTX) as first-line treatment of locally advanced squamous cell c

221 nd safety of nintedanib plus chemotherapy as first-line treatment of malignant pleural mesothelioma (

222 In the first-line treatment of mCRC, patients with RAS wild-typ

223 ficant benefit to the Nordic FLOX regimen in first-line treatment of mCRC.

224 ne, cyclophosphamide, and rituximab (FCR) is first-line treatment of medically fit chronic lymphocyti

225 Dietary advice is the cornerstone in first-line treatment of metabolic diseases.

226 linical benefit in terms of increased PFS in first-line treatment of metastatic breast cancer, with a

227 ssed on or following adjuvant trastuzumab or first-line treatment of metastatic disease with trastuzu

228 of bevacizumab to gemcitabine-docetaxel for first-line treatment of metastatic uLMS failed to improv

229 In the first-line treatment of metastatic urothelial carcinoma,

230 chemotherapy with and without necitumumab as first-line treatment of mSqCLC, to evaluate the costs an

231 benefit from VEGF pathway inhibitors in the first-line treatment of ovarian cancer is likely to incr

232 tuximab to oxaliplatin-based chemotherapy in first-line treatment of patients with advanced colorecta

233 R tyrosine kinase inhibitor gefitinib in the first-line treatment of patients with advanced EGFR-muta

234 palbociclib in combination with letrozole as first-line treatment of patients with advanced, oestroge

235 l compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR mutation-posi

236 progression-free survival over gefitinib in first-line treatment of patients with EGFR-mutation-posi

237 apy regimens versus those regimens alone for first-line treatment of patients with human epidermal gr

238 free survival, and objective response in the first-line treatment of patients with KRAS codon 12/13 (

239 imumab over standard-of-care chemotherapy in first-line treatment of patients with metastatic melanom

240 The main component of the first-line treatment of pemphigus vulgaris is high doses

241 icity, the withdrawal of chloroquine (CQ) as first-line treatment of Plasmodium falciparum infections

242 sinin-based combination therapy (ACT) is the first-line treatment of Plasmodium falciparum malaria.

243 c model comparing 4 treatment strategies for first-line treatment of recurrent CDI in a population wi

244 tion cephalosporins have been considered the first-line treatment of SBP.

245 acy between cisplatin and carboplatin in the first-line treatment of SCLC, but there are differences

246 in- or carboplatin-based chemotherapy in the first-line treatment of small-cell lung cancer (SCLC) re

247 aromatase inhibitor, a standard of care for first-line treatment of these patients.

248 lycemic drug metformin, widely prescribed as first-line treatment of type II diabetes mellitus, has l

249 (FCR) together are established as a standard first-line treatment of younger patients with chronic ly

250 metrexed could be an effective and tolerable first-line treatment option for patients with advanced n

251 These results support nilotinib as a first-line treatment option for patients with newly diag

252 -small-cell lung cancer and represents a new first-line treatment option for this disease.

253 Afatinib should be considered as a first-line treatment option for this patient population.

254 e witnessed checkpoint inhibition becoming a first-line treatment option with US Food and Drug Admini

255 for managing CAD and may be considered as a first-line treatment option, depending on individual pat

256 acin-based sequential quadruple therapies as first-line treatment options and determine factors assoc

257 ility of remission or treatment failure with first-line treatment options for major depression.

258 Cladribine therapy in first-line treatment or later.

259 ational guidelines recommend azithromycin as first-line treatment, rapid spread of macrolide resistan

260 n-based combination therapies (ACTs) are the first-line treatment recommended by the WHO to treat Pla

261 INTERPRETATION: For patients with first-line treatment-refractory relapsing-remitting mult

262 rts the use of EFV as the preferred NNRTI in first-line treatment regimen for HIV treatment, particul

263 tase inhibitors (NNRTIs) are usually part of first-line treatment regimens for human immunodeficiency

264 ozoite killing drugs such as primaquine into first-line treatment regimens is predicted to cause subs

265 RAL in first-line treatment regimens results in rapid immune re

266 crobials that were previously recommended as first-line treatment regimens, and current treatment opt

267 Overall, choosing among the atypical APDs as first-line treatment represents the best course for schi

268 nical trial of aripiprazole augmentation for first-line treatment-resistant late-life depression (Inc

269 t randomized study strongly suggests that in first-line treatment, rituximab combined with steroids i

270 Re-treatment options are available, but first-line treatment strategies should be optimized to e

271 ought to evaluate the effect of BDex+AA as a first-line treatment strategy on mortality in patients w

272 If new drugs replace the current first-line treatment, then existing classifications of r

273 the use of levofloxacin/moxifloxacin in the first-line treatment; this could be due to the varied re

274 The policy option to change the standard first-line treatment to a boosted protease inhibitor reg

275 nt Plasmodium vivax in Indonesia has shifted first-line treatment to artemisinin-based combination th

276 docetaxel (HT; n = 70) or T-DM1 (n = 67) as first-line treatment until disease progression or unacce

277 tuzumab plus docetaxel (pertuzumab group) as first-line treatment until the time of disease progressi

278 The average length of first-line treatment was 21 weeks, with no difference be

279 First-line treatment was switched from SP to artemether-

280 bance (2D); 3) in patients refractory to the first-line treatments, we suggest incremental doses of h

281 nd 48% (P = .03); complete response rates to first-line treatment were 86% and 68% (P = .01); and 8-y

282 Patients with RR-HL age >/= 60 years at first-line treatment were included in this analysis.

283 kin lymphoma who had responded completely to first-line treatment were randomly assigned (1:1) to fol

284 pporting evidence, lithium should remain the first-line treatment when prescribing a relapse-preventi

285 Hydroxyurea and interferon may be used as first-line treatments, whereas busulfan is reserved for

286 Oral propranolol is now the first-line treatment, which should be administered as ea

287 with colorectal cancer starting adjuvant or first-line treatment with a chemotherapy combination con

288 First-line treatment with a vascular endothelial growth

289 gression-free and overall survival following first-line treatment with alkylating agents and purine a

290 jor congenital malformations associated with first-line treatment with an artemisinin derivative comp

291 oes not interfere with clinical benefit from first-line treatment with bevacizumab plus chemotherapy

292 Although patients often respond initially to first-line treatment with chemotherapy plus monoclonal a

293 At present, first-line treatment with EGFR TKIs (gefitinib, erlotini

294 First-line treatment with either first-generation antips

295 aclitaxel should be offered to patients with first-line treatment with FOLFIRINOX, an ECOG PS 0 to 1,

296 rinotecan should be offered to patients with first-line treatment with gemcitabine plus NAB-paclitaxe

297 RECOMMENDATION 1: ACP recommends first-line treatment with pelvic floor muscle training i

298 In this randomized phase II study, first-line treatment with T-DM1 for patients with HER2-p

299 For pseudophakic patients, first-line treatment with triamcinolone seems to be the

300 owledge, the effectiveness of rituximab as a first-line treatment without systemic corticosteroids ha